Lead generation and optimization:

 

Utilizing a novel screening technology developed by Longevica in 2011, we are discovering and optimizing EF2K inhibitors. The technology is based on a proprietary method for detecting eEF2K phosphorylation activity in vitro (US Patent # 8,349,576). We are screening compound libraries for potential leads as well as conducting a medicinal chemistry effort to generate novel compounds with eEF2K inhibitory properties.

 

 

Proof-of-concept studies:

 

Ongoing animal studies include the measuring and analysis of the cardioprotective effects of eEF2K inhibitors in chemotherapy-induced cardiac damage.

 

 

Patents:

 

US Patent 6,346,406: Elongation factor-2 kinase (EF-2 kinase), and methods of use therefor. Ryazanov, AG, Hait, W.N, & Pavur, K.S. Issued on February 12, 2002.

 

US Patent 7,087,427: Mammalian alpha-kinase proteins, nucleic acids and diagnostic and therapeutic uses thereof. Ryazanov, A. Issued on August 8, 2006.

 

US Patent 8,030,286: Methods and means for increasing resistance to cell damage. Ryazanov, A. Chu, H-P. Issued on October 4, 2011.

 

US Patent 7,785,878: Mammalian alpha-kinase proteins, nucleic acids and diagnostic and therapeutic uses thereof. Ryazanov, A. Issued on August 31, 2010.

 

US Patent 8,349,576: eEF2K assays for identifying compounds that inhibit eEF2K activity. Ryazanov, A. Turk, B. Issued on January 8, 2013.

 

 

Longevica is looking for collaborators and partners to jointly commercialize eEF2K inhibitors.